The company said it can isolate nearly pure tumor DNA from blood, which potentially solves a key bottleneck in liquid biopsy.
Shares of VolitionRx (VNRX) surged more than 70% in pre-market trading on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said it was successful in isolating more than 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients.
VNRX stock is on track to breach its 100-day moving average for the first time since Oct. 8, 2025.
Source: TradingView
The company submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA. This addresses a key challenge in liquid biopsy, where most circulating DNA typically comes from healthy cells.
“Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA,” said Jake Micallef, Chief Scientific Officer of Volition.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years,” Micallef added.
Get updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
